Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.

Schlieren (Zurich), Switzerland, May 18, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the commercial launch of MagnetOs Easypack Putty in the U.S., at the 22nd Annual Meeting of the International Society for the Advancement of Spine Surgery (ISASS), held in the Bahamas, June 1-4 2022.

MagnetOs Easypack Putty is a soft and moldable formulation that is provided in an open-ended dispenser and is ready to use with no requirement for thawing or mixing with blood or bone marrow aspirate. The moldable and cohesive properties of MagnetOs Easypack Putty make it ideal for packing into voids of the posterolateral spine during spinal fusion surgery. It becomes the third commercial MagnetOs product, alongside MagnetOs Granules and MagnetOs Putty.

Human-derived products, such as cell-based allografts, and recombinant protein products, such as bone morphogenetic proteins, need to be stored in freezers and then carefully thawed under a strict protocol prior to or during surgery. In contrast, MagnetOs Easypack Putty can be stored on the shelf of the operating room at room temperature and used immediately from the packaging, saving important time during surgical procedures.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “We are pleased to launch this new formulation of our MagnetOs bone graft, which strengthens our market position by offering surgeons a broader set of options for intra-operative properties. MagnetOs Easypack Putty is the third line extension to our MagnetOs product family with moldable and cohesive properties which make it ideal for packing into voids of the posterolateral spine during spinal fusion surgery. It’s simple storage requirements and ease of use, save time and remove potential complications from procedures for the benefit of both surgeons and patients.”

ISASS works to expedite acceptance of the latest innovations in spine surgery by both the insurance industry and government. Although much of this works takes place in the U.S., these successes are typically taken to countries around the globe to promote and ensure that the science and patient care is the same across nations.